RegeneRx Biopharmaceuticals to Present Several Papers at Second International Symposium on Thymosins in Health and Disease
BETHESDA, Md.-(Business Wire)-September 24, 2009 - REGENERX BIOPHARMACEUTICALS, INC. (NYSE Amex:RGN) (www.regenerx.com) announced today that it will participate in the Second International Symposium on Thymosins in Health and Disease. This conference will take place from September 30, through October 2, 2009 in Catania, Italy. The forum is sponsored by The George Washington University School of Medicine and Health Sciences, in collaboration with the University of Rome “Tor Vergata” and The University of Catania. This meeting brings together many of the leading researchers in the U.S., Europe, and Asia to report on advances that have been made in the chemistry, biology, and clinical application of thymosins in health and disease. A schedule of presentations may be viewed at http://www.gwumc.edu/cehp/thymosin09/schedule.html.
David Crockford, RegeneRx’s vice president of clinical and regulatory affairs will be presenting a paper entitled, “Thymosin beta 4 – An Overview of its Structure, Function, and Biological Properties Supporting Current and Future Clinical Applications.”
Dr. Hynda Kleinman, a member of RegeneRx’s scientific advisory board and former researcher at the National Institutes of Health will be giving a talk on Thymosin beta 4 and its role in stem cell maturation.
Other members of the Company’s scientific advisory board, as well as independent research teams throughout the world, will present new data on Tβ4, some of which will be related to RegeneRx’s current clinical programs. The Company intends to issue a press release reviewing relevant new data on Tβ4 presented at the symposium.
“Since much of our product development is based on Tβ4, we look forward to hearing about the research being conducted by third parties,” stated J.J. Finkelstein, RegeneRx’s president and chief executive officer. “Based on the rapidly growing body of data published in the scientific literature over the past few years, we believe Tβ4 offers a potential solution to various important medical indications and we remain strongly focused on its clinical development in dermal, ophthalmic, and cardiovascular indications.”
About RegeneRx Biopharmaceuticals, Inc.
RegeneRx is focused on the discovery and development of novel peptides to accelerate tissue and organ repair. Currently, RegeneRx is developing three product candidates, RGN-137, RGN-259 and RGN-352 for dermal, ophthalmic, and cardiovascular tissue repair, respectively. RegeneRx is also developing RGN-457 for use in pulmonary indications such as cystic fibrosis. These product candidates are based on Tβ4, a synthetic copy of a 43-amino acid, naturally occurring peptide, in part, under an exclusive world-wide license from the National Institutes of Health. RegeneRx holds over 60 world-wide patents and patent applications related to novel peptides. It is currently sponsoring Phase II clinical trials for dermal and ophthalmic wound healing and recently completed a Phase I clinical trial supporting systemic delivery of RGN-352 for acute cardiovascular indications. RegeneRx is also developing novel peptides for the cosmeceutical industry based on its experience with Tβ4 and its biological activities in the skin.
RegeneRx Technology Background
Tβ4 is a synthetic version of a naturally occurring peptide present in virtually all human cells. It is a first-in-class multi-faceted molecule that promotes endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition, and down-regulates inflammation. RegeneRx has identified several molecular variations of Tβ4 that may affect the aging of skin, among other properties, and could be important candidates as active ingredients in pharmaceutical and consumer products. Researchers at the National Institutes of Health, and at other academic institutions throughout the U.S., have published numerous scientific articles indicating Tβ4’s in vitro and in vivo efficacy in accelerating wound healing and tissue protection under a variety of conditions. Abstracts of scientific papers related to Tβ4’s mechanisms of action may be viewed at RegeneRx’s web page: www.regenerx.com.
Forward-Looking Statements
Any statements in this press release that are not historical facts are forward-looking statements made under the provisions of The Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the words “project,” “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “should,” “would,” “could,” “will,” ”may” or other similar expressions and include statements regarding the safety and efficacy of RGN-137, RGN-259, RGN-352, and RGN-457. Clinical results and/or commercial benefit may differ materially from those described in presentations by researchers at the Thymosin meeting, some of whom collaborate with RegeneRx. The Company’s product candidates may not demonstrate safety and/or efficacy in current or future clinical trials or as a result of various important factors described in the Company’s filings with the Securities and Exchange Commission (“SEC”), including those identified in the "Risk Factors" sections of the annual report on Form 10-K for the year ended December 31, 2008 and such other items described in the filed Company’s quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2009 or other filings it makes with the SEC. Any forward-looking statements in this press release represent the Company’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. The Company anticipates that subsequent events and developments may cause its views to change, and the Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.
 |
 |
 |
|
||
 |
|
 |
|
||
Search Our News Using Google Search
Can't find what you want? Try using Google:
